<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 15, 2000
COR THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware 0-19290 94-3060271
(State of jurisdiction) (Commission File No.) (IRS Employer
Identification No.)
256 East Grand Avenue
South San Francisco, California 94080
(Address of principal executive offices and zip code)
Registrant's telephone number, including area code: (650) 244-6800
<PAGE> 2
Item 5. Other Events
On February 15, 2000, COR Therapeutics, Inc., a Delaware corporation (the
"Company"), announced that it intended to raise approximately $150,000,000
through a private placement of convertible subordinated notes. See the
Company's press release, attached hereto as Exhibit 99.1.
Item 7. Exhibits
Exhibit 99.1 Press Release, dated February 15, 2000, entitled "COR
Therapeutics, Inc. Announces Proposed $150 Million Convertible Subordinated
Note Offer."
2
<PAGE> 3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
COR THERAPEUTICS, INC.
Dated: February 16, 2000 By: /s/ Peter S. Roddy
-----------------------------
Peter S. Roddy
Vice President, Finance
3
<PAGE> 1
EXHIBIT 99.1
COR Therapeutics, Inc. Announces Proposed $150
Million Convertible Subordinated Note Offer
South San Francisco, CA; Feb. 15, 2000--COR Therapeutics,
Inc. (Nasdaq:CORR) announced today that it proposes to offer a new issue
of $150 million of Convertible Subordinated Notes due 2007 (the "Notes").
The Notes will be convertible into COR Therapeutics Common Stock, at the option
of the holder, at a price to be determined. The Company may also issue up to an
additional $50 million of Notes to cover over-allotments in connection with the
offering.
COR Therapeutics intends to use the proceeds of the sale for marketing and
selling activities related to INTEGRILIN(R) (eptifibatide) Injection, research
and development activities and general corporate purposes.
The Notes have not been registered under the Securities Act of 1933, as amended,
or applicable state securities laws, and unless so registered, may not be
offered or sold in the United States, except pursuant to an applicable exemption
from the registration requirements of the Securities Act of 1933, as amended,
and applicable state securities laws.
This press release shall not constitute an offer to sell or the solicitation of
an offer to buy the Notes. This press release is being issued pursuant to and in
accordance with Rule 135c under the Securities Act of 1933, as amended.
In addition to the historical information contained herein, this press release
contains forward-looking statements that involve risks and uncertainties. Actual
results of the Company's activities may differ significantly from the potential
results discussed in such forward-looking statements. These forward-looking
statements are based on current expectations and the Company assumes no
obligation to update this information. A full discussion of COR Therapeutics'
operations and financial condition, and specific factors that could cause the
Company's actual performance to differ from current expectations, can be found
in the Company's SEC reports, including, but not limited to, the Company's
Report on Form 10-Q for the quarter ended September 30, 1999, and Report on Form
10-K for the year ended December 31, 1998.
INTEGRILIN(R) is a registered trademark of COR Therapeutics, Inc.
Contact:
COR Therapeutics, Inc.
Jacquelyn A. Jeffries
(650) 244-6893
or Burns McClellan, Inc.
Lisa Burns (Investors)
Jonathan M. Nugent
(212) 213-0006
4
